Back to Journals » Biologics: Targets and Therapy

Biologics: Targets and Therapy

ISSN: 1177-5491


Journal Articles:

- 509 records -

Osteoimmune Interaction and TH-1/TH-2 Ratio in Jawbone Marrow Defects: An Underestimated Association – Original Research

Lechner J, von Baehr V, Notter F, Schick F

Biologics: Targets and Therapy 2024, 18:147-161

Published Date: 6 June 2024

LncRNA GAS5 Modulates the Progression of Glioma Through Repressing miR-135b-5p and Upregulating APC

Zhang J, You Q, Wang Y, Ji J

Biologics: Targets and Therapy 2024, 18:129-142

Published Date: 23 May 2024

Successful Fistula Closure After Treatment with Colostomy and Infliximab in a Patient with Ulcerative Colitis Complicated by Rectovaginal Fistula

Katsube S, Matsumoto S, Misawa M, Kakizawa N, Hashimoto R, Mizutani T, Matsumoto K, Yoshikawa S, Mashima H

Biologics: Targets and Therapy 2024, 18:107-113

Published Date: 6 May 2024

TNFSF13B rs9514828 C>T Polymorphism is Associated with Incidence of Atherosclerosis and Therapeutic Outcomes in Patients with Systemic Lupus Erythematosus

Fajar DR, Rostinawati T, Hamijoyo L, Sahiratmadja E, Amalia R, Barliana MI

Biologics: Targets and Therapy 2024, 18:95-106

Published Date: 3 May 2024

Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy

Soberanis Pina P, Lheureux S

Biologics: Targets and Therapy 2024, 18:79-93

Published Date: 21 March 2024

MDMX in Cancer: A Partner of p53 and a p53-Independent Effector

Lin W, Yan Y, Huang Q, Zheng D

Biologics: Targets and Therapy 2024, 18:61-78

Published Date: 31 January 2024

Advances with Platelet-Rich Plasma for Bone Healing

Bacevich BM, Smith RDJ, Reihl AM, Mazzocca AD, Hutchinson ID

Biologics: Targets and Therapy 2024, 18:29-59

Published Date: 25 January 2024

Recent Advancements in Reducing the Off-Target Effect of CRISPR-Cas9 Genome Editing

Asmamaw Mengstie M, Teshome Azezew M, Asmamaw Dejenie T, Teshome AA, Tadele Admasu F, Behaile Teklemariam A, Tilahun Mulu A, Mekonnen Agidew M, Adugna DG, Geremew H, Abebe EC

Biologics: Targets and Therapy 2024, 18:21-28

Published Date: 18 January 2024

Effect of N-Acetylcysteine on Cisplatin Toxicity: A Review of the Literature

Zavala-Valencia AC, Velasco-Hidalgo L, Martínez-Avalos A, Castillejos-López M, Torres-Espíndola LM

Biologics: Targets and Therapy 2024, 18:7-19

Published Date: 16 January 2024

Successful Response to Golimumab in a Case of Relapsing Polychondritis Overlapping with Ulcerative Colitis

Kojima S, Matsumoto S, Koito Y, Miura T, Sekine M, Uehara T, Asano T, Yamaguchi Y, Mashima H

Biologics: Targets and Therapy 2024, 18:1-6

Published Date: 12 January 2024

The Effect of Two Years of Secukinumab Treatment on Bone Metabolism in Patients with Radiographic Axial Spondyloarthritis: Results from Daily Clinical Practice

Siderius M, Kieskamp SC, Wink F, Kroese FGM, Arends S, Spoorenberg A

Biologics: Targets and Therapy 2023, 17:161-166

Published Date: 14 December 2023

Tocilizumab Vs Methotrexate in a Cohort of Patients Affected by Active GCA: A Comparative Clinical and Ultrasonographic Study

Grazzini S, Conticini E, Falsetti P, D'Alessandro M, Sota J, Terribili R, Baldi C, Fabiani C, Bargagli E, Cantarini L, Frediani B

Biologics: Targets and Therapy 2023, 17:151-160

Published Date: 1 December 2023

Serum LINC00152 and UCA1 in HCV-Induced Hepatocellular Carcinoma: Clinical Significance and Prognostic Value

Shehab-Eldeen S, Essa A, Arafat ES, Sleem AS, Alhosary AA, Darwish E, Essa A, Al-Omair OA, Al-Khoufi EA, Al Abdulqader AK, Nada A

Biologics: Targets and Therapy 2023, 17:137-149

Published Date: 13 October 2023

Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis

Haddad A, Stein N, Lavi I, Shynkar L, Bergman I, Feldhamer I, Cohen AD, Saliba W, Zisman D

Biologics: Targets and Therapy 2023, 17:129-136

Published Date: 4 October 2023

New Uracil Analog with Exocyclic Methylidene Group Can Reverse Resistance to Taxol in MCF-7 Cancer Cells

Długosz-Pokorska A, Perlikowska R, Janecki T, Janecka A

Biologics: Targets and Therapy 2023, 17:69-83

Published Date: 15 May 2023

Treating Alpelisib-Induced Hyperinsulinemia in Patients with Advanced Breast Cancer – A Real-Life Experience

Percik R, Oedegaard Smith C, Leibovici A, Shai A

Biologics: Targets and Therapy 2023, 17:61-67

Published Date: 3 May 2023

Hypereosinophilic Dermatitis: Successful Treatment with Dupilumab

Wu C, Zhang J, Zhao Y

Biologics: Targets and Therapy 2023, 17:57-60

Published Date: 20 April 2023

Demonstration of Safety in Wild Type Mice of npFOXF1, a Novel Nanoparticle-Based Gene Therapy for Alveolar Capillary Dysplasia with Misaligned Pulmonary Veins

Kohram F, Deng Z, Zhang Y, Reza AA, Li E, Kolesnichenko OA, Shukla S, Ustiyan V, Gomez-Arroyo J, Acharya A, Shi D, Kalinichenko VV, Kenny AP

Biologics: Targets and Therapy 2023, 17:43-55

Published Date: 20 March 2023

Elevated Serum Vinculin in Patients with HBV/HCV-Associated Liver Cirrhosis and Hepatocellular Carcinoma: A Pilot Study

Essa A, Essa ES, El-deeb SM, Seleem HEM, Al Sahlawi M, Al-Omair OA, Shehab-Eldeen S

Biologics: Targets and Therapy 2023, 17:23-32

Published Date: 19 March 2023

The Cancer Driver Genes IDH1 and IDH2 and CD204 in WHO-Grade 4 Astrocytoma: Crosstalk Between Cancer Metabolism and Tumour Associated Macrophage Recruitment in Tumour Microenvironment

Kurdi M, Mulla N, Katib Y, Alsinani T, Hakamy S, MJ Addas B, Malibary H, Halawa TF, S Farhan M, Faizo E, Baeesa S

Biologics: Targets and Therapy 2023, 17:15-22

Published Date: 5 February 2023

Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis

van Leeuwen JR, Popov T, Obergfell A, Rabelink TJ, Teng YKO

Biologics: Targets and Therapy 2023, 17:11-14

Published Date: 25 January 2023

Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices

Haroon MM, Hegazy GA, Hassanien MA, Shaker O, Hussein WH

Biologics: Targets and Therapy 2023, 17:1-9

Published Date: 18 January 2023

Adherence to Subcutaneous Anti-Tumour Necrosis Factor Treatment in a Cohort of Patients with Rheumatoid Arthritis Before and After the Implementation of a Comprehensive Care Model

Santos-Moreno P, Sánchez-Vanegas G, Monterrosa-Blanco A, Rodríguez-Vargas GS, Rivero M, Rodriguez P, Calixto OJ, Rojas-Villarraga A, Castro CA

Biologics: Targets and Therapy 2022, 16:199-209

Published Date: 21 November 2022

TNF Inhibitors Exert a “Hidden” Beneficial Effect in the Cardiovascular Lipoprotein Profile of RA Patients

Calvo Alén J, Lavin-Gomez BA, Aurrecoechea E, Guerra Ruiz AR, Martínez Taboada V, Gómez Gerique J

Biologics: Targets and Therapy 2022, 16:187-197

Published Date: 17 October 2022

Phage Therapy: A Different Approach to Fight Bacterial Infections

Hibstu Z, Belew H, Akelew Y, Mengist HM

Biologics: Targets and Therapy 2022, 16:173-186

Published Date: 6 October 2022

Biosimilars: Science, Implications, and Potential Outlooks in the Middle East and Africa

Batran RA, Elmoshneb M, Hussein AS, Hussien OM, Adel F, Elgarhy R, Morsi MI

Biologics: Targets and Therapy 2022, 16:161-171

Published Date: 6 October 2022

Emerging Therapies for Huntington’s Disease – Focus on N-Terminal Huntingtin and Huntingtin Exon 1

van der Bent ML, Evers MM, Vallès A

Biologics: Targets and Therapy 2022, 16:141-160

Published Date: 30 September 2022

A Review on Inflammatory Bowel Diseases: Recent Molecular Pathophysiology Advances

Abdulla M, Mohammed N

Biologics: Targets and Therapy 2022, 16:129-140

Published Date: 12 September 2022

Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis

Alorfi NM, Alourfi MM

Biologics: Targets and Therapy 2022, 16:119-127

Published Date: 5 August 2022

Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? – A Cohort Study in a Colombian Population

Santos-Moreno P, Martinez S, Ibata L, Villarreal L, Rodríguez-Florido F, Rivero M, Rojas-Villarraga A, Galarza-Maldonado C

Biologics: Targets and Therapy 2022, 16:107-117

Published Date: 13 July 2022

Successful Treatment of an Adult with Atopic Dermatitis and Lamellar Ichthyosis Using Dupilumab

Binkhonain FK, Aldokhayel S, BinJadeed H, Madani A

Biologics: Targets and Therapy 2022, 16:85-88

Published Date: 23 June 2022

Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician

Saleh A, Ansari U, Abughazaleh S, Glassner K, Abraham BP

Biologics: Targets and Therapy 2022, 16:67-83

Published Date: 17 June 2022

Biosimilars in Pediatric IBD: Updated Considerations for Disease Management

Dipasquale V, Cucinotta U, Romano C

Biologics: Targets and Therapy 2022, 16:57-66

Published Date: 13 June 2022

Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis

Mykoniatis I, Tsiakaras S, Samarinas M, Anastasiadis A, Symeonidis EN, Sountoulides P

Biologics: Targets and Therapy 2022, 16:47-55

Published Date: 20 May 2022

Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response

Dabi YT, Andualem H, Degechisa ST, Gizaw ST

Biologics: Targets and Therapy 2022, 16:35-45

Published Date: 9 May 2022

Progress in Biological Therapies for Adult-Onset Still’s Disease

Galozzi P, Bindoli S, Doria A, Sfriso P

Biologics: Targets and Therapy 2022, 16:21-34

Published Date: 21 April 2022

A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon

Temraz S, Nasr F, Kattan J, Abigerges D, Moukadem W, Farhat F, Maatouk L, Chahine G, Shamseddine A

Biologics: Targets and Therapy 2022, 16:7-15

Published Date: 21 February 2022

Efficacy of Anti-Tumor Necrosis Factor-α Therapy Against Intestinal Behçet’s Disease Complicated by Recurrent Enterocutaneous Fistulae

Kashima H, Matsumoto S, Kojima S, Koito Y, Miura T, Ishii T, Mashima H

Biologics: Targets and Therapy 2022, 16:1-6

Published Date: 2 February 2022

Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population

Berman J, Furer V, Berman M, Isakov O, Zisman D, Haddad A, Elkayam O

Biologics: Targets and Therapy 2021, 15:463-470

Published Date: 18 November 2021

State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer

Basile D, Simionato F, Cappetta A, Garattini SK, Roviello G, Aprile G

Biologics: Targets and Therapy 2021, 15:451-462

Published Date: 3 November 2021

More articles